Over-expression of Egfr is closely correlated to poor prognosis in tunisian patients with non-small cell lung Adenocarcinoma

Journal of Immunoassay and Immunochemistry

Volumn 35, Issue 3, 2014, Pages 256-268

  Arfaoui, Amira ^a   Kriaa, Lilia ^b   Znaidi, Nadia ^a   Gritli, Sami ^a   Bouacha, Hend ^a   Zermani, Rachida ^a   Rammeh, Soumaya ^a  

^a CHARLES NICOLLE HOSPITAL   (Tunisia)

^b Department of Biology Central University   (Tunisia)

Author keywords

EGFR expression; immunohistochemistry; lung cancer; marker; prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUNISIA;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN; RESPIRATORY MUCOSA; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896956231     PISSN: 15321819     EISSN: 15324230     Source Type: Journal    
DOI: 10.1080/15321819.2013.848813     Document Type: Article

References (40)

1. Fojo, T. Multiple Paths to a Drug Resistance Phenotype: Mutations, Translocations, Deletions and Amplification of Coding Genes or Promoter Regions, Epigenetic Changes and microRNAs. Drug. Resist. Updat. 2007, 10, 59-67.
2. Devesa, S.S.; Bray, F.I.; Vizcaino, A.P.; Parkin, D.M. International Lung Cancer Trends by Histologic Type: Male: Female Differences Diminishing and Adenocarcinoma rates rising. Int. J. Cancer. 2005, 117, 294-299.
3. Parkin, D.M.; Bray, F.I.; Devasa, S.S. Cancer Burden in the Year 2000: The Global Picture. Eur. J. Cancer. 2001, 37(Suppl 8), S4-66.
4. Ohta, Y.; Shimizu, Y.; Matsumoto, I.; Tamura, M.; Oda, M.; Watanabe, G. Retrospective Review of Lung Cancer Patients with Pleural Dissemination after Limited Operations Combined with Parietal Pleurectomy. J. Surg. Oncol. 2005, 91, 237-242.
5. st ed.; Travis, W.D.; Brambilla, E.; Müller-Hermelink, H.K.; Harris, C.C., Eds.; IARC Press: Lyon, France, 2004; Ch. 1, 12-15.
6. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R.P.; Baselga, J. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients with Advanced Non-Small-Cell-Lung Cancer. J. Clin. Oncol. 2003, 21, 2237-2246.
7. Paez, J.G.; Jänne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. Science 2004, 304, 1497-1500.
8. Soh, J.; Toyooka, S.; Aoe, K.; Asano, H.; Ichihara, S.; Katayama, H.; Hiraki, A.; Kiura, K.; Aoe, M.; Sano, Y.; Sugi, K.; Shimizu, N.; Date, H. Usefulness of EGFR Mutation Screening in Pleural Fluid to Predict the Clinical Outcome of Gefitinib Treated Patients with Lung Cancer. Int. J. Cancer 2006, 119, 2353-2358.
9. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Settleman, J.; Haber, D.A. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
10. Pao, W.; Miller, V.A.; Politi, K.A.; Riely, G.J.; Somwar, R.; Zakowski, M.F.; Kris, M.G.; Varmus, H. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib is Associated with a Second Mutation in the EGFR Kinase Domain. PLoS. Med. 2005, 2, 73.
11. Massarelli, E.; Varella-Garcia, M.; Tang, X.; Xavier, A.C.; Ozburn, N.C.; Liu, D.D.; Bekele, B.N.; Herbst, R.S.; Wistuba, I.I. KRAS Mutation is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors In Non-Small-Cell Lung Cancer. Clin. Cancer Res. 2007, 13, 2890-2896.
12. Chou, Y.T.; Lin, H.H.; Lien, Y.C.; Wang, Y.H.; Hong, C.F.; Kao, Y.R.; Lin, S.C.; Chang, Y.C.; Lin, S.Y.; Chen, S.J.; Chen, H.C.; Yeh, S.D.; Wu, C.W. EGFR Promotes Lung Tumorigenesis by Activating miR-7 through a Ras/ERK/Myc Pathway that Targets the Ets2 Transcriptional Repressor ERF. Cancer. Res. 2010, 70, 8822-8831.
13. Salomon, D.S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal Growth Factor-Related Peptides and Their Receptors in Human Malignancies. Crit. Rev. Oncol. Hematol. 1995, 19, 183-232.
14. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; Sarkaria, I.; Singh, B.; Heelan, R.; Rusch, V.; Fulton, L.; Mardis, E.; Kupfer, D.; Wilson, R.; Kris, M.; Varmus, H. EGF Receptor Gene Mutations are Common in Lung Cancers from "Never Smokers" and are Associated with Sensitivity of Tumors to Gefitinib and Erlotinib. Proc. Natl. Acad. Sci. USA. 2004, 101, 13306-13311.
15. Rosell, R.; Moran, T.; Queralt, C.; Porta, R.; Cardenal, F.; Camps, C.; Majem, M.; Lopez-Vivanco, G.; Isla, D.; Provencio, M.; Insa, A.; Massuti, B.; Gonzalez-Larriba J.L.; Paz-Ares, L.; Bover, I.; Garcia-Campelo, R.; Moreno, M.A.; Catot, S.; Rolfo, C.; Reguart, N.; Palmero, R.; Sánchez, J.M.; Bastus, R.; Mayo, C.; Bertran-Alamillo, J.; Molina, M.A.; Sanchez, J.J.; Taron, M.; Spanish Lung Cancer Group. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. N. Engl. J. Med. 2009, 361, 958-967.
16. Inoue, A; Kobayashi, K.; Usui, K.; Maemondo, M.; Okinaga, S.; Mikami, I.; Ando, M.; Yamazaki, K.; Saijo, Y.; Gemma, A.; Miyazawa, H.; Tanaka, T.; Ikebuchi, K.; Nukiwa, T.; Morita, S.; Hagiwara, K.; North East Japan Gefitinib Study Group. First-Line Gefitinib for Patients with Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations without Indication for Chemotherapy. J. Clin. Oncol. 2009, 27, 1394-1400.
17. Costanzo, R.; Piccirillo, M.C.; Sandomenico, C.; Carillio, G.; Montanino, A.; Daniele, G.; Giordano, P.; Bryce, J.; De Feo, G.; Di Maio, M.; Rocco, G.; Normanno, N.; Perrone, F.; Morabito, A. Gefitinib in Non-Small Cell Lung Cancer. J. Biomed. Biotechnol. 2011, 8, 152-169.
18. Yaren, A.; Oztop, I.; Kargi, A.; Ulukus, C.; Onen, A.; Sanli, A.; Binicier, O.; Yilmaz, U.; Alakavuklar, M. Bax, bcl-2 and c-kit Expression in Non-Small Cell Lung Cancer and Their Effects on Prognosis. Int. J. Clin. Pract. 2006, 60, 675-682.
19. Kassouf, W.; Black, P.C.; Tuziak, T.; Bondaruk, J.; Lee, S.; Brown, G.A.; Adam, L.;Wei, C.; Baggerly, K.; Bar-Eli, M.; McConkey, D.; Czerniak, B.; Dinney, C.P. Distinctive Expression Pattern of ErbB Family Receptors Signifies an Aggressive Variant of Bladder Cancer. J. Urol. 2008, 179, 353-358.
20. Kraus, M.H.; Issing, W.; Miki, T.; Popescu, N.C.; Aaronson, S.A. Isolation and Characterization of ERBB3, a Third Member of ERBB/Epidermal Growth Factor Receptor Family: Evidence for Overexpression in a Subset of Human Mammary Tumors. Proc. Natl. Acad. Sci. USA 1989, 86, 9193-9197.
21. Nicholson, R.I.; Gee, J.M.; Harper, M.E. EGFR and Cancer Prognosis. Eur. J. Cancer. 2001, 37(Suppl. 4), S9-15.
22. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab Monotherapy and Cetuximab Plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. N. Engl. J. Med. 2004, 351, 337-345.
23. Neumann, J.; Feuerhake, F.; Kayser, G.; Wiech, T.; Aumann, K.; Passlick, B.; Fisch, P.; Werner, M.; Zur Hausen A. Gene Expression Profiles of Lung Adenocarcinoma Linked to Histopathological Grading and Survival but not to EGF-R Status: A Microarray Study. BMC Cancer 2010, 10, 77.
24. Ciardiello, F.; Tortora, G. Epidermal Growth Factor Receptor (EGFR) as a Target in Cancer Therapy: Understanding the Role of Receptor Expression and Other Molecular Determinants that Could Influence the Response to Anti-EGFR Drugs. Eur. J. Cancer 2003, 39, 1348-1354.
25. Jänne, P.A.; Engelman, J.A.; Johnson, B.E. Epidermal Growth Factor Receptor Mutations in Non-Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology. J. Clin. Oncol. 2005, 23, 3227-3234.
26. Amoêdo, N.; Castelo-Branco, M.; Paschoal, M.; Pezzuto, P.; Esperança, A.B.; Rumjanek, V.M.; Rumjanek, F.D. Expression of ABC Transporters, p53, Bax, Bcl-2 in an Archival Sample of Non-Small Cell Lung Cancer Bearing a Deletion in the EGFR gene. Int. J. Mol. Med. 2009, 23, 609-614.
27. Gazdar, A.F. Personalized Medicine and Inhibition of EGFR Signaling in Lung Cancer. N. Engl. J. Med. 2009, 361, 1018-1020.
28. Calvo, E.; Baselga, J. Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. J. Clin. Oncol. 2006, 24, 2158-2163.
29. Dacic, S.; Flanagan, M.; Cieply, K.; Ramalingam, S.; Luketich, J.; Belani, C.; Yousem, S.A. Significance of EGFR Protein Expression and Gene Amplification in Non-Small Cell Lung Carcinoma. Am. J. Clin. Pathol. 2006, 125, 860-865.
30. Ettinger, D.S. Clinical Implications of EGFR Expression in the Development and Progression of Solid Tumors: Focus on Non-Small Cell Lung Cancer. Oncologist 2006, 11, 358-373.
31. Gazdar, A.F. Activating and Resistance Mutations of EGFR in Non-Small-Cell Lung Cancer: Role in Clinical Response to EGFR Tyrosine Kinase Inhibitors. Oncogene 2009, 28, 24-31.
32. Subramanian, J.; Govindan, R. Lung Cancer in Never Smokers: A Review. J. Clin. Oncol. 2007, 25, 561-570.
33. Subramanian, J.; Govindan, R. Molecular Genetics of Lung Cancer in People who have Never Smoked. Lancet Oncol. 2008, 9, 676-682.
34. Ciardiello, F.; Tortora, G. EGFR Antagonists in Cancer Treatment. N. Engl. J. Med. 2008, 358, 1160-1174.
35. Linardou, H.; Dahabreh, I.J.; Kanaloupiti, D.; Siannis, F.; Bafaloukos, D.; Kosmidis, P.; Papadimitriou, C.A.; Murray, S. Assessment of Somatic k-RAS Mutations as a Mechanism Associated with Resistance to EGFR-Targeted Agents: A Systematic Review and Meta-Analysis of Studies in Advanced Non-Small-Cell Lung Cancer and Metastatic Colorectal Cancer. Lancet Oncol. 2008, 9, 962-972.
36. Meert, A.P.; Martin, B.; Delmotte, P.; Berghmans, T.; Lafitte, J.J.; Mascaux, C.; Paesmans, M.; Steels, E.; Verdebout, J.M.; Sculier, J.P. The Role of EGF-R Expression on Patient Survival in Lung Cancer: A Systematic Review with Meta-Analysis. Eur. Respir. J. 2002, 20, 975-981.
37. Nakamura, H.; Kawasaki, N.; Taguchi, M.; Kabasawa, K. Survival Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis. Thorax 2006, 61, 140-145.
38. Montero, A.J.; Diaz-Montero, C.M.; Mao, L.; Youssef, E.M.; Estecio, M.; Shen, L.; Issa, J.P. Epigenetic Inactivation of EGFR by CpG Island Hypermethylation in Cancer. Cancer. Biol. Ther. 2006, 5, 1494-1501.
39. Nikolaidis, G.; Raji, O.; Markopoulou, S.; Gosney, J.R.; Bryan, J.;Warburton, C.;Walshaw, M.; Sheard, J.; Field, J.K.; Liloglou, T. DNA Methylation Biomarkers Offer Improved Diagnostic Efficiency in Lung Cancer. Cancer. Res. 2012, 72, 5692-5701.
40. Leng, S.; Do, K.; Yingling, M.C.; Picchi, M.A.; Wolf, H.J.; Kennedy, T.C.; Feser, W.J.; Baron, A.E.; Franklin, W.A.; Brock, M.V.; Herman, J.G.; Baylin, S.B.; Byers, T.; Stidley, C.A.; Belinsky, S.A. Defining a Gene Promoter Methylation Signature in Sputum for Lung Cancer Risk Assessment. Clin. Cancer. Res. 2012, 18, 3387-3395.